Coming October 2: SITC releases abstract titles with each presenting author’s institution (nearly 1,300 last year). We’ll add them to this guide once they’re out.

Leerink Partners at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Leerink Partners takes part in 4 sessions at SITC 2026 in Phoenix. Its program focuses on new drugs in development, especially immune cell engagers, bispecific antibodies and antibody-drug conjugates. It also covers careers in venture capital and biotech investing.

OrganizationSITC 2026 Attendance
leerink.com
Investors
Investment bank specializing in healthcare and life sciences.
Workshop
Thu Nov 5
8:00am–4:15pm
New Agents in Development and Emerging Technologies
  1. 8:00am–9:50amSession I: Cell Therapies and Technologies
  2. 10:05am–11:50amSession II: Immune Cell Engagers and Bispecifics
  3. 1:30pm–2:55pmSession III: ADC/iADC
  4. 3:10pm–4:15pmSession IV: Emerging Technologies – Incorporation into Clinical Trials
Workshop
Thu Nov 5
10:05am–11:50am
Session II: Immune Cell Engagers and Bispecifics
Valley of the Sun Ballroom
New agents
  1. 10:05am–10:20amIntroduction/History/Approved Drugs/Almost Approved - Overview TalkJohnson & Johnson
  2. 10:20am–10:30amFrom Bench to Bispecific: The Rilvegostomig Program at a GlanceAstraZeneca
  3. 10:30am–10:40amUnlocking the Immune System: Advanced Combination Strategies for Cancer ImmunotherapyRegeneron
  4. 10:40am–10:50amIndustry Talk with Clinical DataGenmab
  5. 10:50am–11:00am(PD1xTGFb)
  6. 11:00am–11:10amInitial Clinical Results with T-cell Receptor (TCR)-based Bispecific T-cell Engagers (TCERs) Targeting PRAME and MAGEA4/8 in Advanced Solid TumorsImmatics
  7. 11:30am–11:50amDebate (Cell Therapy vs. Engagers)Johnson & Johnson
Session
Thu Nov 5
12:00pm–1:30pm
Workshop
Thu Nov 5
1:30pm–2:55pm
Session III: ADC/iADC
Valley of the Sun Ballroom
New agents
  1. 1:30pm–1:45pmLearning from History: Designing Antibody Drug Conjugates for ImmunotherapyUniversity of Michigan
  2. 1:45pm–1:55pmIza-bren: BMS's First Bispecific ADC, and Pumitamig, the PD-L1×VEGF-A Bispecific AntibodyBristol Myers Squibb
  3. 1:55pm–2:05pm(TM) ASP2998, a TROP2-targeted ADC with Dual Payloads-Preclinical DataAstellas Pharma
  4. 2:05pm–2:15pmTAK-928 (IBI-363): A First-in-class PD-1/IL-2 α-bias Bispecific Fusion ProteinTakeda
  5. 2:15pm–2:25pmPD-1 × IL-15 Bispecific Antibodies: Synergistic Immunoactivation in Solid TumorsSanofi
  6. 2:25pm–2:35pmIndustry Talk with Clinical DataGenmab

Explore the full SITC 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Phoenix. Leave your work email and we’ll be in touch.

Privacy

Download the full SITC 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Leerink Partners

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the Society for Immunotherapy of Cancer (SITC). Submit a correction